Company: PTPI
Filing Date: 2025-04-11
Form Type: 8-K
Source: 0001104659-25-034283
Chunk: 0

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-04-11
Form: 8-K
Item: Item 3.03
Chunk 0
---
Item 3.03 Material Modification to Rights of Security Holders.

To the extent required by Item 3.03 of Form 8-K, the information contained
in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As reported below under Item 5.07 of this Current
Report on Form 8-K, the Company held a special meeting of stockholders on April 10, 2025 (the “ Special Meeting”), at which
the Company’s stockholders approved an amendment (the “ Incentive Plan Amendment”) to the Third Amendment to the Petros
Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan (the “ Incentive Plan”) to increase the
aggregate number of shares of common stock, par value $0.0001 per share (the “ Common Stock”) available for the grant of awards
under the Incentive Plan by 1,000,000,000, to a total of 1,002,760,000 shares of Common Stock.

For more information about the Incentive Plan
Amendment, see the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on March
18, 2025 (the “ Proxy Statement”), the relevant portions of which are incorporated herein by reference. The foregoing description
of the Incentive Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of
the Incentive Plan Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference
herein.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year.

At the Company’s Special Meeting, the Company’s stockholders
approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Share Increase Amendment”)
to increase the number of authorized shares of the Common Stock from 250,000,000 shares to 7,000,000,000 and to make a corresponding change
to the number of authorized shares of the Company’s capital stock. Following the Special Meeting, on April 11, 2025, the Company
filed the Share Increase